Alto Neuroscience ANRO Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid
Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid?
- Alto Neuroscience (ANRO) reported costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid of $233K in Q1 2026.
- What does costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid mean?
- Represents accrued but unpaid costs associated with equity financing transactions that have been recognized but not yet settled in cash. This metric highlights short-term liabilities arising from capital-raising activities. It is important for understanding the full cost of financing before the cash impact is realized on the balance sheet.